UA85527C2 - Separated antibody or fragment of antibody that are specifically bound to fragment of polypeptide rg1, immunoconjugate that includes separated antibody of fragment of antibody, means for selective destruction of cell, treatment of prostate cancer, diagnostics of prostate cancer and its metastases in patient, application of antibody and immunoconjugate as therapeutic agent - Google Patents
Separated antibody or fragment of antibody that are specifically bound to fragment of polypeptide rg1, immunoconjugate that includes separated antibody of fragment of antibody, means for selective destruction of cell, treatment of prostate cancer, diagnostics of prostate cancer and its metastases in patient, application of antibody and immunoconjugate as therapeutic agentInfo
- Publication number
- UA85527C2 UA85527C2 UA2002075749A UA2002075749A UA85527C2 UA 85527 C2 UA85527 C2 UA 85527C2 UA 2002075749 A UA2002075749 A UA 2002075749A UA 2002075749 A UA2002075749 A UA 2002075749A UA 85527 C2 UA85527 C2 UA 85527C2
- Authority
- UA
- Ukraine
- Prior art keywords
- antibody
- fragment
- immunoconjugate
- prostate cancer
- polypeptide
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
Abstract
The invention relates to separated antibody or fragment of antibody that are specifically bound to fragment of polypeptide RG1. Also the invention relates to immunoconjugate that includes separated antibody or fragment of antibody that are specifically bound to fragment of polypeptide RG1. Besides, the invention relates to the method for selective destruction of cell that expresses polypeptide, to the method for prostate cancer providing injection to the patient of therapeutically effective quantity of immunoconjugate, methods of diagnostics of prostate cancer and its metastases in patient using the superexpression RG1 metering. Also the method relates to application of antibody and immunoconjugate as therapeutic agent.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17237099P | 1999-12-16 | 1999-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
UA85527C2 true UA85527C2 (en) | 2009-02-10 |
Family
ID=50556928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UA2002075749A UA85527C2 (en) | 1999-12-16 | 2000-12-15 | Separated antibody or fragment of antibody that are specifically bound to fragment of polypeptide rg1, immunoconjugate that includes separated antibody of fragment of antibody, means for selective destruction of cell, treatment of prostate cancer, diagnostics of prostate cancer and its metastases in patient, application of antibody and immunoconjugate as therapeutic agent |
Country Status (1)
Country | Link |
---|---|
UA (1) | UA85527C2 (en) |
-
2000
- 2000-12-15 UA UA2002075749A patent/UA85527C2/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001072962A3 (en) | Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods | |
WO2004032857A8 (en) | Antibody therapy | |
MXPA05012011A (en) | Therapeutic use of anti-cs1 antibodies. | |
TW200728465A (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
SG155054A1 (en) | Human anti- neutralizing antibodies as selective pathway inhibitors | |
IL139700A0 (en) | Immunotherapeutic composition and method for the treatment of prostate cancer | |
HK1016018A1 (en) | Cross-reacting monoclonal antibodies specific for e-selectin and p-selectin | |
WO2001008636A8 (en) | Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein | |
AU3327701A (en) | Humanized anti-ccr2 antibodies and methods of use therefor | |
MXPA02011656A (en) | Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods. | |
MY150237A (en) | Cripto blocking antibodies and uses thereof | |
DK0528931T3 (en) | Humanized chimeric anti-ICAM-1 antibodies, methods for their preparation and their use | |
DK0942740T3 (en) | Combination therapy using a TFN-binding protein to treat TFN-mediated diseases | |
MY151032A (en) | Treatment of tnf? related disorders | |
WO2006029219A3 (en) | Human monoclonal anti-ctla4 antibodies in cancer treatment | |
WO2005120557A3 (en) | Inhibition of macrophage-stimulating protein receptor (ron) | |
MXPA04006517A (en) | Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours. | |
GEP20135826B (en) | Novel antibodies used to treat cancer | |
ATE412756T1 (en) | METHOD FOR DIAGNOSING CANCER USING A CHIMERIC TOXIN | |
TW200517124A (en) | Fully human antibodies against human 4-1BB | |
WO2006088464A3 (en) | A method of using an anti-cd137 antibody as an agent for radioimmunotherapy or radioimmunodetection | |
SI1684770T1 (en) | Oligo-beta-(1,3)-glucan and monoclonal antibodies against cancer | |
PL330705A1 (en) | Tie-2 receptor ligands (ligand-3 tie; ligand-4 tie) and their application | |
DE60238435D1 (en) | TARGETED THROMBOSE THROUGH TISSUE FACTOR POLYPEPTIDES | |
IL207012A0 (en) | Diagnosis and therapy of cancer using sgp28-related molecules |